{"generic":"Ceftazidime","drugs":["Ceftazidime","Fortaz","Tazicef"],"mono":{"0":{"id":"111733-s-0","title":"Generic Names","mono":"Ceftazidime"},"1":{"id":"111733-s-1","title":"Dosing and Indications","sub":[{"id":"111733-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Bacterial meningitis:<\/b> 2 g IV every 8 hr<\/li><li><b>Bacterial septicemia:<\/b> very severe life-threatening infections, especially in immunocompromised; 2 g IV every 8 hr<\/li><li><b>Cystic fibrosis - Pneumonia due to Pseudomonas:<\/b> 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><li><b>Cystic fibrosis - Pneumonia due to Pseudomonas:<\/b> very severe life-threatening infections, especially in immunocompromised; 2 g IV every 8 hr<\/li><li><b>Female genital infection:<\/b> 2 g IV every 8 hr<\/li><li><b>Infection of bone - Infectious disorder of joint:<\/b> 2 g IV every 12 hr<\/li><li><b>Infection of bone - Infectious disorder of joint:<\/b> very severe life-threatening infections, especially in immunocompromised; 2 g IV every 8 hr<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> mild, 0.5 g to 1 g IV\/IM every 8 hr<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> severe life-threatening infections, 2 g IV every 8 hr<\/li><li><b>Infectious disease of abdomen:<\/b> 2 g IV every 8 hr<\/li><li><b>Lower respiratory tract infection:<\/b> very severe life-threatening infections, especially in immunocompromised; 2 g IV every 8 hr<\/li><li><b>Lower respiratory tract infection:<\/b> uncomplicated pneumonia, 0.5 g to 1 g IV\/IM every 8 hr<\/li><li><b>Urinary tract infectious disease:<\/b> uncomplicated, 250 mg IV\/IM every 12 hr<\/li><li><b>Urinary tract infectious disease:<\/b> complicated, 500 mg IV\/IM every 8 to 12 hr<\/li><\/ul>"},{"id":"111733-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Bacterial meningitis:<\/b> neonates 0 to 7 days of age, 100 to 150 mg\/kg\/day IV divided every 8-12 hr; neonates 8 to 28 days, 150 mg\/kg\/day IV divided every 8 hr (guideline dosing)<\/li><li><b>Bacterial meningitis:<\/b> infants and children, 150 mg\/kg\/day IV divided every 8 hr (guideline dosing); MAX 6 g\/day<\/li><li><b>Bacterial septicemia:<\/b> neonates (0 to 4 weeks), 30 mg\/kg IV every 12 hr<\/li><li><b>Bacterial septicemia:<\/b> 1 month to 12 years, 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><li><b>Cystic fibrosis - Pneumonia due to Pseudomonas:<\/b> neonates (0 to 4 weeks), 30 mg\/kg IV every 12 hr<\/li><li><b>Cystic fibrosis - Pneumonia due to Pseudomonas:<\/b> 1 month to 12 years, 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><li><b>Female genital infection:<\/b> neonates (0 to 4 weeks), 30 mg\/kg IV every 12 hr<\/li><li><b>Female genital infection:<\/b> 1 month to 12 years, 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><li><b>Infection of bone - Infectious disorder of joint:<\/b> neonates (0 to 4 weeks), 30 mg\/kg IV every 12 hr<\/li><li><b>Infection of bone - Infectious disorder of joint:<\/b> 1 month to 12 years, 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> neonates (0 to 4 weeks), 30 mg\/kg IV every 12 hr<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue:<\/b> 1 month - 12 years, 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><li><b>Infectious disease of abdomen:<\/b> neonates (0 to 4 weeks), 30 mg\/kg IV every 12 hr<\/li><li><b>Infectious disease of abdomen:<\/b> 1 month to 12 years, 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><li><b>Lower respiratory tract infection:<\/b> neonates (0 to 4 weeks), 30 mg\/kg IV every 12 hr<\/li><li><b>Lower respiratory tract infection:<\/b> 1 month to 12 years, 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><li><b>Urinary tract infectious disease:<\/b> neonates (0 to 4 weeks), 30 mg\/kg IV every 12 hr<\/li><li><b>Urinary tract infectious disease:<\/b> 1 month to 12 years, 30 to 50 mg\/kg IV every 8 hr; MAX 6 g\/day<\/li><\/ul>"},{"id":"111733-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment (adults):<\/b> give initial 1 g IV loading dose; CrCl 31 to 50 mL\/min, 1 g every 12 hr; CrCl 16 to 30 mL\/min, 1 g every 24 hr; CrCl 6 to 15 mL\/min, 0.5 g every 24 hr; CrCl less than 5 mL\/min, 0.5 g every 48 hr<\/li><li><b>renal impairment (pediatric patients):<\/b> modify dose frequency consistent with adult recommendations<\/li><li><b>hemodialysis:<\/b> give initial 1 g loading dose followed by 1 g after each hemodialysis period<\/li><li><b>peritoneal dialysis:<\/b> give initial 1 g IV loading dose followed by 0.5 g IV every 24 hr or add 250 mg to 2 L of dialysis fluid<\/li><\/ul>"},{"id":"111733-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bacterial meningitis<\/li><li>Bacterial septicemia<\/li><li>Cystic fibrosis - Pneumonia due to Pseudomonas<\/li><li>Female genital infection<\/li><li>Infection of bone - Infectious disorder of joint<\/li><li>Infection of skin AND\/OR subcutaneous tissue<\/li><li>Infectious disease of abdomen<\/li><li>Lower respiratory tract infection<\/li><li>Urinary tract infectious disease<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bronchiectasis<\/li><li>Chronic purulent otitis media<\/li><li>Febrile neutropenia<\/li><li>Melioidosis<\/li><\/ul>"}]},"3":{"id":"111733-s-3","title":"Contraindications\/Warnings","sub":[{"id":"111733-s-3-9","title":"Contraindications","mono":"hypersensitivity to ceftazidime products\/cephalosporins<br\/>"},{"id":"111733-s-3-10","title":"Precautions","mono":"<ul><li>hypersensitivity to penicillins<\/li><li>elevated levels in renal impairment; risk for seizures, encephalopathy<\/li><li>patients with history of gastrointestinal disease, particularly colitis<\/li><li>patients with risk factors for altered prothrombin time; renal or hepatic impairment, poor nutritional status, prolonged course of antibiotic therapy<\/li><\/ul>"},{"id":"111733-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"111733-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"111733-s-4","title":"Drug Interactions","sub":{"1":{"id":"111733-s-4-14","title":"Major","mono":"<ul>Warfarin (probable)<\/ul>"},"2":{"id":"111733-s-4-15","title":"Moderate","mono":"<ul>Chloramphenicol (probable)<\/ul>"}}},"5":{"id":"111733-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Diarrhea<br\/><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Pseudomembranous enterocolitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Asterixis, Coma, Encephalopathy, Myoclonia, Seizure<\/li><\/ul>"},"6":{"id":"111733-s-6","title":"Drug Name Info","sub":{"0":{"id":"111733-s-6-17","title":"US Trade Names","mono":"<ul><li>Fortaz<\/li><li>Tazicef<\/li><\/ul>"},"2":{"id":"111733-s-6-19","title":"Class","mono":"<ul><li>3rd Generation Cephalosporin<\/li><li>Antibiotic<\/li><\/ul>"},"3":{"id":"111733-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"111733-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"111733-s-7","title":"Mechanism Of Action","mono":"Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic which inhibits enzymes responsible for cell-wall synthesis. It is bactericidal against a wide range of gram-negative and gram-positive organisms but is highly stable to clinically important plasmid and chromosomal beta-lactamases produced by these organisms. It is also active against many strains resistant to ampicillin and other cephalosporins.<br\/>"},"8":{"id":"111733-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"111733-s-8-23","title":"Absorption","mono":"IM: time to peak concentration, approximately 1 h (mean) <br\/>"},"1":{"id":"111733-s-8-24","title":"Distribution","mono":"Protein binding: less than 10% <br\/>"},"3":{"id":"111733-s-8-26","title":"Excretion","mono":"<ul><li>Renal: approximately 80% to 90% unchanged over a 24-hour period<\/li><li>Dialyzable: yes (hemodialysis); yes (peritoneal dialysis)<\/li><\/ul>"},"4":{"id":"111733-s-8-27","title":"Elimination Half Life","mono":"<ul><li>(IM), approximately 2 h<\/li><li>(IV), approximately 1.9 h<\/li><\/ul>"}}},"9":{"id":"111733-s-9","title":"Administration","mono":"<ul><li><b>Intramuscular<\/b><br\/><ul><li>reconstitute with one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection<\/li><li>reconstitute 500 mg vial with 1.5 mL diluent, or 1 g vial with 3 mL diluent, for a final concentration of 280 mg\/mL<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>(bolus) reconstitute 500 mg, 1 g, or 2 g vial with 5.3 mL, 10 mL, or 10 mL Sterile Water for Injection, respectively, for a final concentration of 100 mg\/mL, 100 mg\/mL, or 170 mg\/mL, respectively<\/li><li>(bolus) inject IV over 3 to 5 min or give through existing tubing containing D5W, NS, or other compatible IV solution<\/li><li>(infusion) add reconstituted solution to an IV container with one of the compatible IV fluids<\/li><\/ul><\/li><\/ul>"},"10":{"id":"111733-s-10","title":"Monitoring","mono":"<ul><li>fever<\/li><li>symptomatic improvement<\/li><li>CBC<\/li><li>hepatic\/renal function<\/li><li>previous hypersensitivity to other beta-lactam antibiotics<\/li><li>prothrombin time in patients at risk<\/li><li>signs of antibiotic-associated diarrhea, other superinfections<\/li><li>signs of serum-sickness-like reactions<\/li><\/ul>"},"11":{"id":"111733-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Injection Powder for Solution: 1 GM, 2 GM, 6 GM, 500 MG<\/li><li>Intravenous Powder for Solution: 1 GM, 2 GM, 6 GM<\/li><\/ul><\/li><li><b>Fortaz<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM, 6 GM, 500 MG<br\/><\/li><li><b>Novaplus Tazicef<\/b><br\/>Injection Powder for Solution: 1 GM, 2 GM, 6 GM<br\/><\/li><li><b>PremierPro Rx cefTAZidime<\/b><br\/>Injection Powder for Solution: 1 GM<br\/><\/li><li><b>Tazicef<\/b><br\/><ul><li>Injection Powder for Solution: 1 GM, 2 GM<\/li><li>Intravenous Powder for Solution: 6 GM<\/li><\/ul><\/li><\/ul>"},"12":{"id":"111733-s-12","title":"Toxicology","sub":[{"id":"111733-s-12-31","title":"Clinical Effects","mono":"<b>CEPHALOSPORINS<\/b><br\/>OVERDOSE: Acute ingestion of large doses of cephalosporins may result in nausea, vomiting, diarrhea, and abdominal pain. Seizures have developed after parenteral overdose. ADVERSE EFFECTS: COMMON: Hypersensitivity reactions, including anaphylaxis, may commonly occur with therapy; oral exposures are less likely to cause severe allergic reactions than parenteral exposures. Seizures have also been reported following therapeutic administration. Prolonged prothrombin times, thrombocytopenia, and coagulopathies associated with a qualitative platelet defect and aggregation abnormalities have been reported following IV cephalosporin therapy. Pseudocholelithiasis may follow intravenous administration of ceftriaxone. Several cases of fatal hemolytic reactions following intravenous ceftriaxone therapy have been reported in children with serious hematologic abnormalities.<br\/>"},{"id":"111733-s-12-32","title":"Treatment","mono":"<b>CEPHALOSPORINS <\/b><br\/><ul><li>Decontamination: Generally not indicated in patients with no underlying health problems. Activated charcoal may be necessary for patients with underlying renal insufficiency.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Monitor renal function, electrolytes, CBC including platelets.<\/li><li>Anaphylaxis: Mild to moderate allergic reactions may be treated with antihistamines with or without inhaled beta adrenergic agonists, corticosteroids or epinephrine. Diphenhydramine: ADULTS: 50 mg orally, IV, or IM initially, then 25 to 50 mg orally every 4 to 6 hours for 24 to 72 hours. CHILDREN: 1.25 mg\/kg orally, IV, or IM initially, then 5 mg\/kg\/day orally in 4 divided doses for 24 to 72 hours. Treatment of severe anaphylaxis also includes oxygen supplementation, aggressive airway management, epinephrine, ECG monitoring, and IV fluids.<\/li><li>Seizure: IV benzodiazepines, barbiturates<\/li><li>Blood coagulation disorder: Vitamin K, fresh frozen plasma<\/li><li>Intrathecal injection: Treat seizures with anticonvulsants (benzodiazepines, propofol, phenobarbital); endotracheal intubation and mechanical ventilation as needed. Keep the patient upright if possible. Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults. Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free normal saline or lactated ringers). For large overdoses, consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline or lactated ringers through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 to 150 mL\/hr). Dexamethasone 4 mg intravenously every 6 hours to prevent arachnoiditis.<\/li><\/ul>"},{"id":"111733-s-12-33","title":"Range of Toxicity","mono":"<b>CEPHALOSPORINS<\/b><br\/>TOXICITY: Serious toxicity is unlikely following large oral doses of cephalosporins. Crystalluria and hematuria has been described in a 3-year-old boy who ingested 104 mg\/kg of cephalexin. THERAPEUTIC DOSE: Varies with agent. CEPHALEXIN: CHILDREN:  25 to 100 milligrams\/kilogram\/24 hours orally, up to a maximum of 4 grams\/day, divided every 6 hours. <br\/>"}]},"13":{"id":"111733-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report signs\/symptoms serum-sickness-like reactions (rash, urticaria, arthralgia, fever, malaise, enlarged lymph nodes).<\/li><li>Advise patient to report severe diarrhea and consult healthcare professional prior to taking anti-diarrhea medicine. Other superinfection signs\/symptoms should be reported as well.<\/li><\/ul>"}}}